Author pages are created from data sourced from our academic publisher partnerships and public sources.
Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein.
Adhesion of Staphylococcus aureus to blood vessels under shear stress requires von Willebrand factor (VWF). Several bacterial factors have been proposed to interact with VWF, including VWF-binding… Expand
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at… Expand
Dextran sulfate triggers platelet aggregation via direct activation of PEAR1
Abstract Dextran sulfate (DxS; Mr 500 kD) induces fibrinogen receptor (αIIbβ3) activation via CLEC-2/Syk signaling and via a Syk-independent SFK/PI3K/Akt-dependent tyrosine kinase pathway in human… Expand
Hematologic Malignancies in Pregnancy
Cancer and especially hematological cancer during pregnancy is infrequent and its management is difficult for patients and their families, but also for their physicians since two lives with different… Expand
PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway.
Platelet endothelial aggregation receptor-1 (PEAR1) participates in platelet aggregation via sustaining αIIbβ3 activation. To investigate the role of PEAR1 in platelet formation, we monitored and… Expand
Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis.
- C. Vandenbriele, A. Kauskot, +7 authors P. Verhamme
- Medicine, Biology
- Cardiovascular research
- 1 October 2015
AIMS Platelet endothelial aggregation receptor-1 (PEAR1) is a cell membrane protein, expressed on platelets and endothelial cells (ECs). PEAR1 sustains αIIbβ3 activation in aggregating platelets and… Expand
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism
- T. Vanassche, C. Vandenbriele, K. Peerlinck, P. Verhamme
- Expert opinion on pharmacotherapy
- 6 March 2015
Introduction: Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or… Expand
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
TB-402 is a long-acting monoclonal antibody that partially inhibits factor VIII. A single administration of TB-402 was effective and well-tolerated for the prevention of venous thromboembolism (VTE)… Expand
PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population
BackgroundPlatelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, plays a role in platelet contact-induced activation, sustained… Expand
The treatment of hematologic malignancies in pregnancy
Cancer and especial l y hemat ol ogical cancer during pregnancy is infrequent and it s management is difficul t for pat ient s, t heir famil ies and t heir physicians. When t erminat ion of pregnancy… Expand